Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer

Breast cancer is the most common malignancy in women globally. The increasing worldwide incidence of this type of cancer illustrates the challenge it represents for healthcare providers. Therefore, new tumor markers are constantly being sought. The aim of this study was to assess plasma concentratio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Grażyna E. Będkowska, Ewa Gacuta, Monika Zbucka-Krętowska, Paweł Ławicki, Maciej Szmitkowski, Adam Lemancewicz, Joanna Motyka, Agnieszka Kobus, Monika Chorąży, Marlena Paniczko, Sławomir Ławicki
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	breast cancer VEGF CA 15-3 tumor marker Medicine R
Acceso en línea:	https://doaj.org/article/df1e340d24e943d2b7e2c00a79203594
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:df1e340d24e943d2b7e2c00a79203594
record_format	dspace
spelling	oai:doaj.org-article:df1e340d24e943d2b7e2c00a792035942021-11-25T18:02:58ZPlasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer10.3390/jcm102254522077-0383https://doaj.org/article/df1e340d24e943d2b7e2c00a792035942021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5452https://doaj.org/toc/2077-0383Breast cancer is the most common malignancy in women globally. The increasing worldwide incidence of this type of cancer illustrates the challenge it represents for healthcare providers. Therefore, new tumor markers are constantly being sought. The aim of this study was to assess plasma concentrations and the diagnostic power of VEGF in 100 patients with early-stage breast cancer, both before and after surgical treatment and during a three-year follow-up. The control groups included 50 subjects with benign breast tumors (<i>fibroadenoma</i>) and 50 healthy women. The VEGF concentration was determined using enzyme-linked immunosorbent assay (ELISA) and the CA 15-3 concentration was determined by chemiluminescent microparticle immunoassay (CMIA). We observed significantly higher preoperative plasma concentrations of VEGF and CA 15-3 in patients with breast cancer. VEGF, similar to CA 15-3, demonstrated high diagnostic utility in the assessment of the long-term efficacy of surgical removal of the tumor. Determinations of VEGF had the highest diagnostic usefulness in the detection of breast cancer recurrence (SE 40%, SP 92%, PPV 67%, NPV 79%). Additionally, the highest values of SE, NPV and AUC were observed during the combined analysis with CA 15-3 (60%; 84%; 0.7074, respectively). Our study suggests a promising diagnostic utility of VEGF in the early stages of breast cancer and in the evaluation of the efficacy of the surgical treatment of breast cancer as well as the detection of breast cancer recurrence, particularly in a combined analysis with CA 15-3 as a new diagnostic panel.Grażyna E. BędkowskaEwa GacutaMonika Zbucka-KrętowskaPaweł ŁawickiMaciej SzmitkowskiAdam LemancewiczJoanna MotykaAgnieszka KobusMonika ChorążyMarlena PaniczkoSławomir ŁawickiMDPI AGarticlebreast cancerVEGFCA 15-3tumor markerMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5452, p 5452 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer VEGF CA 15-3 tumor marker Medicine R
spellingShingle	breast cancer VEGF CA 15-3 tumor marker Medicine R Grażyna E. Będkowska Ewa Gacuta Monika Zbucka-Krętowska Paweł Ławicki Maciej Szmitkowski Adam Lemancewicz Joanna Motyka Agnieszka Kobus Monika Chorąży Marlena Paniczko Sławomir Ławicki Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
description	Breast cancer is the most common malignancy in women globally. The increasing worldwide incidence of this type of cancer illustrates the challenge it represents for healthcare providers. Therefore, new tumor markers are constantly being sought. The aim of this study was to assess plasma concentrations and the diagnostic power of VEGF in 100 patients with early-stage breast cancer, both before and after surgical treatment and during a three-year follow-up. The control groups included 50 subjects with benign breast tumors (<i>fibroadenoma</i>) and 50 healthy women. The VEGF concentration was determined using enzyme-linked immunosorbent assay (ELISA) and the CA 15-3 concentration was determined by chemiluminescent microparticle immunoassay (CMIA). We observed significantly higher preoperative plasma concentrations of VEGF and CA 15-3 in patients with breast cancer. VEGF, similar to CA 15-3, demonstrated high diagnostic utility in the assessment of the long-term efficacy of surgical removal of the tumor. Determinations of VEGF had the highest diagnostic usefulness in the detection of breast cancer recurrence (SE 40%, SP 92%, PPV 67%, NPV 79%). Additionally, the highest values of SE, NPV and AUC were observed during the combined analysis with CA 15-3 (60%; 84%; 0.7074, respectively). Our study suggests a promising diagnostic utility of VEGF in the early stages of breast cancer and in the evaluation of the efficacy of the surgical treatment of breast cancer as well as the detection of breast cancer recurrence, particularly in a combined analysis with CA 15-3 as a new diagnostic panel.
format	article
author	Grażyna E. Będkowska Ewa Gacuta Monika Zbucka-Krętowska Paweł Ławicki Maciej Szmitkowski Adam Lemancewicz Joanna Motyka Agnieszka Kobus Monika Chorąży Marlena Paniczko Sławomir Ławicki
author_facet	Grażyna E. Będkowska Ewa Gacuta Monika Zbucka-Krętowska Paweł Ławicki Maciej Szmitkowski Adam Lemancewicz Joanna Motyka Agnieszka Kobus Monika Chorąży Marlena Paniczko Sławomir Ławicki
author_sort	Grażyna E. Będkowska
title	Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_short	Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_full	Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_fullStr	Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_full_unstemmed	Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer
title_sort	plasma levels and diagnostic utility of vegf in a three-year follow-up of patients with breast cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/df1e340d24e943d2b7e2c00a79203594
work_keys_str_mv	AT grazynaebedkowska plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT ewagacuta plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT monikazbuckakretowska plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT pawełławicki plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT maciejszmitkowski plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT adamlemancewicz plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT joannamotyka plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT agnieszkakobus plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT monikachorazy plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT marlenapaniczko plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer AT sławomirławicki plasmalevelsanddiagnosticutilityofvegfinathreeyearfollowupofpatientswithbreastcancer
_version_	1718411712847151104

Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer

Ejemplares similares